Loading...
Skinshine Cream 30g by Cadila Pharmaceuticals is a prescription‑strength topical depigmentation treatment formulated with Hydroquinone 2% + Mometasone 0.1% + Tretinoin 0.025% to help reduce dark spots, melasma patches and uneven pigmentation while promoting a clearer, brighter skin tone. Designed primarily for targeted hyperpigmentation therapy, this medically supervised cream is used in the treatment of melasma (dark brown patches) and persistent pigmentation concerns on the face and body.
Targets Hyperpigmentation: Effectively reduces dark patches and uneven skin tone by inhibiting excess melanin production.
Promotes Skin Brightening: Encourages a more even, luminous complexion with consistent use under dermatological guidance.
Triple‑Action Formula: Combines a skin‑lightening agent (Hydroquinone), a corticosteroid (Mometasone) to reduce inflammation and irritation, and a retinoid (Tretinoin) to enhance skin cell renewal.
Improved Skin Texture: Tretinoin supports natural exfoliation and cell turnover, leading to smoother, healthier‑looking skin.
Dermatologist‑Recommended: Often prescribed for moderate‑to‑severe melasma and stubborn dark spots that do not respond to gentle over‑the‑counter products.
Hydroquinone reduces the production of melanin, the pigment responsible for skin darkening.
Mometasone alleviates redness, swelling and irritation associated with stubborn pigmentation.
Tretinoin accelerates skin renewal and turnover, promoting clearer and brighter skin.
Cleanse and pat dry the affected area.
Apply a thin layer of Skinshine Cream once daily at night or as prescribed.
Avoid sun exposure; use a broad‑spectrum SPF 30+ sunscreen during daytime.
Avoid contact with eyes, mouth and mucous membranes.
Important: This prescription medication should only be used under dermatological supervision.
For external use only.
Avoid application on broken, ulcerated or infected skin.
Discontinue use if severe irritation occurs and consult a doctor.
Not advised for use during pregnancy or breastfeeding without medical approval.
Burning, irritation, redness, itchiness or dryness at the application site are possible. If severe or persistent, stop use and consult a healthcare professional.
